Lexicon Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Lexicon Pharmaceuticals's estimated annual revenue is currently $483k per year.
- Lexicon Pharmaceuticals's estimated revenue per employee is $1,211
- Lexicon Pharmaceuticals's total funding is $448.5M.
- Lexicon Pharmaceuticals's current valuation is $513.7M. (January 2022)
Employee Data
- Lexicon Pharmaceuticals has 399 Employees.
- Lexicon Pharmaceuticals grew their employee count by 60% last year.
Lexicon Pharmaceuticals's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Owner | Reveal Email/Phone |
2 | Owner | Reveal Email/Phone |
3 | EVP & Chief Scientific Officer | Reveal Email/Phone |
4 | Chief Commercial Officer (CCO) & SVP | Reveal Email/Phone |
5 | Head Investor Relations & Strategy | Reveal Email/Phone |
6 | Head Market Access | Reveal Email/Phone |
7 | EVP, Innovation and Chemical Sciences | Reveal Email/Phone |
8 | SVP and General Counsel | Reveal Email/Phone |
9 | VP and Head Human Resources | Reveal Email/Phone |
10 | SVP, Metabolism Research | Reveal Email/Phone |
Lexicon Pharmaceuticals Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $26.7M | 133 | 20% | N/A | N/A |
#2 | $13.5M | 67 | 6% | N/A | N/A |
#3 | $16.1M | 80 | -2% | N/A | N/A |
#4 | $62.5M | 0 | N/A | N/A | N/A |
#5 | $10.1M | 50 | 6% | N/A | N/A |
#6 | $119.4M | 594 | 27% | N/A | N/A |
#7 | $22.9M | 114 | 8% | N/A | N/A |
#8 | $92.9M | 462 | 8% | N/A | N/A |
#9 | $11.3M | 56 | -8% | N/A | N/A |
#10 | $7M | 35 | 6% | N/A | N/A |
What Is Lexicon Pharmaceuticals?
Lexicon Genetics Incorporated is a biopharmaceutical company focused on the discovery of breakthrough treatments for human disease. Lexicon is using gene knockout technology to systematically discover the physiological functions and medical uses of genes. The Company's gene function discoveries fuel therapeutic discovery programs in cardiovascular disease, diabetes, obesity, immune disorders, neurological disease and cancer. Lexicon has established drug discovery alliances and functional genomics collaborations with leading pharmaceutical and biotechnology companies, research institutes and academic institutions throughout the world to commercialize its technology and further develop its discoveries.
keywords:N/A
$448.5M
Total Funding
399
Number of Employees
$483k
Revenue (est)
60%
Employee Growth %
$513.7M
Valuation
N/A
Accelerator
Lexicon Pharmaceuticals News
Lexicon Pharmaceuticals shared positive data from its Phase III SCORED study on sotagliflozin in reducing cardiovascular death,...
Three years after losing the Type 1 bid, Lexicon has not given up on an approval in that indication, Granowitz said. PharmaSGLT2heart failureheart attackstroke...
THE WOODLANDS, Texas, April 04, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) welcomes new guidelines for the...
CureDuchenne Ventures has already made its first investment in Lexicon Pharmaceuticals. Woodlands, Texas-based Lexicon is running clinical trials of an experimental drug, LX2931, for rheumatoid arthritis but is apparently also exploring the drug’s potential to initiate muscle regeneration in mou ...
Other Companies in The Woodlands
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $122.8M | 401 | 2% | N/A |
#2 | $127.6M | 415 | 7% | N/A |
#3 | $137.5M | 433 | 25% | N/A |
#4 | $139.3M | 455 | 2% | N/A |
#5 | $75M | 502 | 3% | N/A |